Longboard Pharmaceuticals Investor Relations Material

Longboard Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company primarily focused on developing innovative therapies for neurological diseases. Leveraging its expertise in G protein-coupled receptor (GPCR) technology, Longboard Pharmaceuticals aims to create transformative treatments for these conditions. The company's product candidates are designed to be highly selective with the potential to offer significant improvements over existing therapies. Notably, the company was founded as a spin-off from Arena Pharmaceuticals in 2020 to further advance these specialized drug candidates. The company is headquartered in La Jolla, California, and its shares are listed on the NASDAQ.